Pharma BD Deal Intelligence
Defitelio is highly complementary to Jazz Pharmaceuticals' experience in and focus on orphan diseases in the area of hematology/oncology. Transaction expected…
The potential opportunity for sales growth tied to approval and label expansion may wind up making Gentium's billion-dollar price tag a bargain for Jazz —…
FierceBiotech retrospectively framed Jazz's Gentium bet as vindicated when defibrotide finally won FDA approval in 2016, calling it a 'much-delayed rare liver…
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
Jazz to acquire Gentium at $57.00/share cash tender (~$1B); added EU-approved Defitelio for severe hepatic VOD to hematology/oncology orphan portfolio.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Jazz Pharmaceuticals plc / Gentium S.p.A. (this deal) | 2013 | $1.0B | 51 |
| Jazz Pharmaceuticals plc / EUSA Pharma | 2012 | $700M | 60 |
| UCB SA / Celltech Group plc | 2004 | $2.7B | 92 |
| Johnson & Johnson / Centocor Inc. | 1999 | $4.9B | 92 |
| Takeda Pharmaceutical Company Ltd. / Millennium Pharmaceuticals | 2003 | $8.8B | 82 |
| Bristol-Myers Squibb Company / Celgene Corporation | 2019 | $74.0B | 77 |
| Biogen Idec Inc. / Elan Corporation plc (Tysabri rights) | 2013 | $3.2B | 77 |
← Browse all deals · How we score deals
More: 2013 deals · Gastroenterology deals